Strides Pharma - Disappointing Q2; Outlook Weakens: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Strides Pharma Science Ltd. reported another quarter of disappointing performance in Q2 FY22 with U.S. sales declining 17.1% QoQ (down 37.0% YoY) to $34 million.
Despite other segments reporting growth, high raw material and operational costs coupled with lower revenue have severely impacted Ebitda and margins.
The company has delayed its U.S. sales guidance of $220-230 million by several quarters highlighting weakness in the business.
Revenue declined 9.1% YoY to Rs 7.2 billion (our estimate: Rs 7.5 billion) and reported a negative Ebitda and profit after tax.
Strides Pharma has completed the acquisition of manufacturing facility of Endo Pharma New York for ~$24 million along with ~20 commercialised products across nasal sprays, controlled substances, hormones, etc.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.